Review



urinary ifabp concentrations  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems urinary ifabp concentrations
    Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of <t> iFABP </t>
    Urinary Ifabp Concentrations, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 58 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/urinary ifabp concentrations/product/R&D Systems
    Average 94 stars, based on 58 article reviews
    urinary ifabp concentrations - by Bioz Stars, 2026-04
    94/100 stars

    Images

    1) Product Images from "Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease"

    Article Title: Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

    Journal: BMC Gastroenterology

    doi: 10.1186/s12876-022-02334-6

    Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of iFABP
    Figure Legend Snippet: Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of iFABP

    Techniques Used: Clinical Proteomics

    Boxplots A plasma, B urinary iFABP concentrations in Controls and patients with Coeliac during GFD; C plasma, D urinary iFABP concentration in Controls and patients with Colitis and Crohn’s during exclusive enteral nutrition. Coeliac: coeliac disease, ND: newly diagnosed, Crohn’s: Crohn’s disease, Controls: healthy control, mo: month, GFD: gluten-free diet, EEN: exclusive enteral nutrition. Urinary iFABP measurements are expressed after urinary creatinine correction, a: p < 0.05 compared with Controls; b: p < 0.05 compared with ND Coeliac
    Figure Legend Snippet: Boxplots A plasma, B urinary iFABP concentrations in Controls and patients with Coeliac during GFD; C plasma, D urinary iFABP concentration in Controls and patients with Colitis and Crohn’s during exclusive enteral nutrition. Coeliac: coeliac disease, ND: newly diagnosed, Crohn’s: Crohn’s disease, Controls: healthy control, mo: month, GFD: gluten-free diet, EEN: exclusive enteral nutrition. Urinary iFABP measurements are expressed after urinary creatinine correction, a: p < 0.05 compared with Controls; b: p < 0.05 compared with ND Coeliac

    Techniques Used: Clinical Proteomics, Concentration Assay, Control



    Similar Products

    urinary ifabp concentrations  (R&D Systems)
    94
    R&D Systems urinary ifabp concentrations
    Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of <t> iFABP </t>
    Urinary Ifabp Concentrations, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/urinary ifabp concentrations/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    urinary ifabp concentrations - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of iFABP

    Journal: BMC Gastroenterology

    Article Title: Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

    doi: 10.1186/s12876-022-02334-6

    Figure Lengend Snippet: Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of iFABP

    Article Snippet: Plasma and urinary iFABP concentrations were determined using the Quantikine anti-Human-iFABP (DFBP20) (R&D Systems Bio-Techne) ELISA kit according to the manufacturer’s instructions.

    Techniques: Clinical Proteomics

    Boxplots A plasma, B urinary iFABP concentrations in Controls and patients with Coeliac during GFD; C plasma, D urinary iFABP concentration in Controls and patients with Colitis and Crohn’s during exclusive enteral nutrition. Coeliac: coeliac disease, ND: newly diagnosed, Crohn’s: Crohn’s disease, Controls: healthy control, mo: month, GFD: gluten-free diet, EEN: exclusive enteral nutrition. Urinary iFABP measurements are expressed after urinary creatinine correction, a: p < 0.05 compared with Controls; b: p < 0.05 compared with ND Coeliac

    Journal: BMC Gastroenterology

    Article Title: Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

    doi: 10.1186/s12876-022-02334-6

    Figure Lengend Snippet: Boxplots A plasma, B urinary iFABP concentrations in Controls and patients with Coeliac during GFD; C plasma, D urinary iFABP concentration in Controls and patients with Colitis and Crohn’s during exclusive enteral nutrition. Coeliac: coeliac disease, ND: newly diagnosed, Crohn’s: Crohn’s disease, Controls: healthy control, mo: month, GFD: gluten-free diet, EEN: exclusive enteral nutrition. Urinary iFABP measurements are expressed after urinary creatinine correction, a: p < 0.05 compared with Controls; b: p < 0.05 compared with ND Coeliac

    Article Snippet: Plasma and urinary iFABP concentrations were determined using the Quantikine anti-Human-iFABP (DFBP20) (R&D Systems Bio-Techne) ELISA kit according to the manufacturer’s instructions.

    Techniques: Clinical Proteomics, Concentration Assay, Control